News
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...
16h
Investor's Business Daily on MSNBioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark
BioNTech ADR earns the No. 143 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY COVID-19 vaccine for ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...
10d
The Punch on MSNPfizer, BioNTech to pay CureVac, GSK $740m Covid jab settlement
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 ...
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results